Recent advances in human norovirus research and implications for candidate vaccines

References

• Lopman BA, Steele D, Kirkwood CD, et al. The vast and varied global burden of norovirus: prospects for prevention and control. PLoS Med. 2016 Apr;13(4):e1001999.
   PubMed Web of Science ®Google Scholar
• Kapikian AZ, Wyatt RG, Dolin R, et al. Visualization by immune electron microscopy of a 27-nm particle associated with acute infectious nonbacterial gastroenteritis. J Virol. 1972 Nov;10(5):1075–1081.
   PubMed Web of Science ®Google Scholar
• Hallowell BD, Parashar UD, Hall AJ. Epidemiologic challenges in norovirus vaccine development. Hum Vaccin Immunother. 2019;15(6):1279–1283.
   PubMed Web of Science ®Google Scholar
• Ahmed SM, Hall AJ, Robinson AE, et al. Global prevalence of norovirus in cases of gastroenteritis: a systematic review and meta-analysis. Lancet Infect Dis. 2014 Aug;14(8):725–730.
   PubMed Web of Science ®Google Scholar
• Lindsay L, Wolter J, De Coster I, et al. A decade of norovirus disease risk among older adults in upper-middle and high income countries: a systematic review. BMC Infect Dis. 2015 Oct;14(15):425.
   Google Scholar
• Trivedi TK, Desai R, Hall AJ, et al. Clinical characteristics of norovirus-associated deaths: a systematic literature review. Am J Infect Control. 2013 Jul;41(7):654–657.
   PubMed Web of Science ®Google Scholar
• Atmar RL, Estes MK. The epidemiologic and clinical importance of norovirus infection. Gastroenterol Clin North Am. 2006 Jun;35(2):275–90, viii.
   PubMed Web of Science ®Google Scholar
• Mattner F, Sohr D, Heim A, et al. Risk groups for clinical complications of norovirus infections: an outbreak investigation. Clin Microbiol Infect. 2006 Jan;12(1):69–74.
   PubMed Web of Science ®Google Scholar
• Teunis PF, Moe CL, Liu P, et al. Norwalk virus: how infectious is it? J Med Virol. 2008 Aug;80(8):1468–1476.
   PubMed Web of Science ®Google Scholar
• Atmar RL, Opekun AR, Gilger MA, et al. Determination of the 50% human infectious dose for Norwalk virus. J Infect Dis. 2014 Apr 1;209(7):1016–1022.
   PubMed Web of Science ®Google Scholar
• Atmar RL, Opekun AR, Gilger MA, et al. Norwalk virus shedding after experimental human infection. Emerg Infect Dis. 2008 Oct;14(10):1553–1557.
   PubMed Web of Science ®Google Scholar
• Qi R, Huang YT, Liu JW, et al. Global Prevalence of Asymptomatic Norovirus Infection: A Meta-analysis. EClinicalMedicine. 2018;2-3:50–58. Aug-Sep.
   PubMedGoogle Scholar
• Teunis PF, Sukhrie FH, Vennema H, et al. Shedding of norovirus in symptomatic and asymptomatic infections. Epidemiol Infect. 2015 Jun;143(8):1710–1717.
   PubMed Web of Science ®Google Scholar
• Hall AJ, Lopman BA, Payne DC, et al. Norovirus disease in the United States. Emerg Infect Dis. 2013 Aug;19(8):1198–1205.
   PubMed Web of Science ®Google Scholar
• Burke RM, Mattison C, Pindyck T, et al. The Burden of Norovirus in the United States, as Estimated Based on Administrative Data: updates for Medically Attended Illness and Mortality, 2001-2015. Clin Infect Dis. 2020 Apr 14. DOI:10.1093/cid/ciaa438
   Google Scholar
• Kirk MD, Pires SM, Black RE, et al. World Health Organization Estimates of the Global and Regional Disease Burden of 22 Foodborne Bacterial, Protozoal, and Viral Diseases, 2010: A Data Synthesis. PLoS Med. 2015;Dec;12(12):e1001921.
   PubMed Web of Science ®Google Scholar
• Chhabra P, Rouhani S, Browne H, et al. Homotypic and heterotypic protection and risk of re-infection following natural norovirus infection in a highly endemic setting. Clin Infect Dis. 2020 Jan 9. DOI:10.1093/cid/ciaa019
   Web of Science ®Google Scholar
• Bartsch SM, Lopman BA, Ozawa S, et al. Global Economic Burden of Norovirus Gastroenteritis. PloS One. 2016;11(4):e0151219.
   PubMed Web of Science ®Google Scholar
• Harris JP, Iturriza-Gomara M, O’Brien SJ. Estimating Disability-Adjusted Life Years (DALYs) in Community Cases of Norovirus in England. Viruses. 2019 Feb 21;11(2):184.
   Web of Science ®Google Scholar
• Scallan E, Hoekstra RM, Mahon BE, et al. An assessment of the human health impact of seven leading foodborne pathogens in the United States using disability adjusted life years. Epidemiol Infect. 2015 Oct;143(13):2795–2804.
   PubMed Web of Science ®Google Scholar
• Gibney KB, O’Toole J, Sinclair M, et al. Disease burden of selected gastrointestinal pathogens in Australia, 2010. Int J Infect Dis. 2014;28:176–185.
   PubMed Web of Science ®Google Scholar
• Mangen MJ, Bouwknegt M, Friesema IH, et al. Cost-of-illness and disease burden of food-related pathogens in the Netherlands, 2011. Int J Food Microbiol. 2015 Mar 2;196:84–93.
   PubMed Web of Science ®Google Scholar
• Giersing BK, Vekemans J, Nava S, et al. WHO Product Development for Vaccines Advisory Committee. Report from the World Health Organization’s third Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8-10th June 2016. Vaccine. 2017;37(50):7315–7327. DOI:10.1016/j.vaccine.2016.10.090
   Web of Science ®Google Scholar
• Green K. Caliciviridae: the noroviruses. Fields virology. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2013. p. 582–608.
   Google Scholar
• Chhabra P, de Graaf M, Parra GI, et al. Updated classification of norovirus genogroups and genotypes. J Gen Virol. 2019;100(10):1393–1406.
   PubMed Web of Science ®Google Scholar
• Cannon JL, Barclay L, Collins NR, et al. Genetic and Epidemiologic Trends of Norovirus Outbreaks in the United States from 2013 to 2016 Demonstrated Emergence of Novel GII.4 Recombinant Viruses. J Clin Microbiol. 2017 Jul;55(7):2208–2221.
   PubMed Web of Science ®Google Scholar
• Barclay L, Cannon JL, Wikswo ME, et al. Emerging Novel GII.P16 Noroviruses Associated with Multiple Capsid Genotypes. Viruses. 2019;11(6):535.
   PubMed Web of Science ®Google Scholar
• Ludwig-Begall LF, Mauroy A, Thiry E. Norovirus recombinants: recurrent in the field, recalcitrant in the lab - a scoping review of recombination and recombinant types of noroviruses. J Gen Virol. 2018 Aug;99(8):970–988.
   PubMed Web of Science ®Google Scholar
• van Beek J, de Graaf M, Al-Hello H, et al. Molecular surveillance of norovirus, 2005-16: an epidemiological analysis of data collected from the NoroNet network. Lancet Infect Dis. 2018 May;18(5):545–553.
   PubMed Web of Science ®Google Scholar
• Chan MC, Lee N, Hung TN, et al. Rapid emergence and predominance of a broadly recognizing and fast-evolving norovirus GII.17 variant in late 2014. Nat Commun. 2015 Dec;2(6):10061.
   Google Scholar
• Lu J, Sun L, Fang L, et al. Gastroenteritis Outbreaks Caused by Norovirus GII.17, Guangdong Province, China, 2014-2015. Emerg Infect Dis. 2015 Jul;21(7):1240–1242.
   PubMed Web of Science ®Google Scholar
• Singh BK, Koromyslova A, Hefele L, et al. Structural Evolution of the Emerging 2014-2015 GII.17 Noroviruses. J Virol. 2015 Dec 23;90(5):2710–2715.
   PubMed Web of Science ®Google Scholar
• Fu J, Ai J, Jin M, et al. Emergence of a new GII.17 norovirus variant in patients with acute gastroenteritis in Jiangsu, China, September 2014 to March 2015. Euro Surveill. 2015;20(24):21157.
   PubMedGoogle Scholar
• Lu J, Fang L, Sun L, et al. Association of GII.P16-GII.2 Recombinant Norovirus Strain with Increased Norovirus Outbreaks, Guangdong, China, 2016. Emerg Infect Dis. 2017 Jul;23(7):1188–1190.
   PubMed Web of Science ®Google Scholar
• Liu LT, Kuo TY, Wu CY, et al. Recombinant GII.P16-GII.2 Norovirus, Taiwan, 2016. Emerg Infect Dis. 2017 Jul;23(7):1180–1183.
   PubMed Web of Science ®Google Scholar
• Nagasawa K, Matsushima Y, Motoya T, et al. Phylogeny and Immunoreactivity of Norovirus GII.P16-GII.2, Japan, Winter 2016-17. Emerg Infect Dis. 2018 Jan;24(1):144–148.
   PubMed Web of Science ®Google Scholar
• Kwok K, Niendorf S, Lee N, et al. Increased Detection of Emergent Recombinant Norovirus GII.P16-GII.2 Strains in Young Adults, Hong Kong, China, 2016-2017. Emerg Infect Dis. 2017 Nov;23(11):1852–1855.
   PubMed Web of Science ®Google Scholar
• Cheung SKC, Kwok K, Zhang LY, et al. Higher Viral Load of Emerging Norovirus GII.P16-GII.2 than Pandemic GII.4 and Epidemic GII.17, Hong Kong, China. Emerg Infect Dis. 2019 Jan;25(1):119–122.
   PubMed Web of Science ®Google Scholar
• de Graaf M, van Beek J, Vennema H, et al. Emergence of a novel GII.17 norovirus - End of the GII.4 era? Euro Surveill. 2015;20(26):21178.
   PubMedGoogle Scholar
• Jin M, Wu S, Kong X, et al. Norovirus Outbreak Surveillance, China, 2016–2018. Emerg Infect Dis. 2020;26(3):437–445.
   PubMed Web of Science ®Google Scholar
• Hall AJ, Wikswo ME, Manikonda K, et al. Acute gastroenteritis surveillance through the National Outbreak Reporting System, United States. Emerg Infect Dis. 2013 Aug;19(8):1305–1309.
   PubMed Web of Science ®Google Scholar
• Kroneman A, Verhoef L, Harris J, et al. Analysis of integrated virological and epidemiological reports of norovirus outbreaks collected within the Foodborne Viruses in Europe network from 1 July 2001 to 30 June 2006. J Clin Microbiol. 2008 Sep;46(9):2959–2965.
   PubMed Web of Science ®Google Scholar
• Lopman BA, Reacher MH, Van Duijnhoven Y, et al. Viral gastroenteritis outbreaks in Europe, 1995-2000. Emerg Infect Dis. 2003 Jan;9(1):90–96.
   PubMed Web of Science ®Google Scholar
• Hasing ME, Lee BE, Qiu Y, et al. Changes in norovirus genotype diversity in gastroenteritis outbreaks in Alberta, Canada: 2012-2018. BMC Infect Dis. 2019 Feb 19;19(1):177.
   PubMedGoogle Scholar
• Pabbaraju K, Wong AA, Tipples GA, et al. Emergence of a Novel Recombinant Norovirus GII.P16-GII.12 Strain Causing Gastroenteritis, Alberta, Canada. Emerg Infect Dis. 2019 Aug;25(8):1556–1559.
   PubMed Web of Science ®Google Scholar
• Lun JH, Hewitt J, Yan GJH, et al. Recombinant GII.P16/GII.4 Sydney 2012 Was the Dominant Norovirus Identified in Australia and New Zealand in 2017. Viruses. 2018 Oct;10(10):548.
   Web of Science ®Google Scholar
• De Grazia S, Lanave G, Giammanco GM, et al. Sentinel hospital-based surveillance for norovirus infection in children with gastroenteritis between 2015 and 2016 in Italy. PloS One. 2018;13(12):e0208184.
   PubMed Web of Science ®Google Scholar
• Cantelli CP, da Silva MFM, Fumian TM, et al. High genetic diversity of noroviruses in children from a community-based study in Rio de Janeiro, Brazil, 2014-2018. Arch Virol. 2019 May;164(5):1427–1432.
   PubMed Web of Science ®Google Scholar
• Hossain M, Islam M, Aktar S, et al. Emerging recombinant norovirus strains identified among hospitalized actue gastroenteritis patients in Bangladesh. 7th International Calicivirus Conference; 10/ 14/2019; Sydney, Australia; 2019.
   Google Scholar
• Lu L, Zhong H, Xu M, et al. Genetic diversity and epidemiology of Genogroup II noroviruses in children with acute sporadic gastroenteritis in Shanghai, China, 2012-2017. BMC Infect Dis. 2019 Aug 22;19(1):736.
   PubMed Web of Science ®Google Scholar
• Pogan R, Dulfer J, Uetrecht C. Norovirus assembly and stability. Curr Opin Virol. 2018 Aug;31:59–65.
   PubMed Web of Science ®Google Scholar
• Simmons K, Gambhir M, Leon J, et al. Duration of immunity to norovirus gastroenteritis. Emerg Infect Dis. 2013 Aug;19(8):1260–1267.
   PubMed Web of Science ®Google Scholar
• Cannon JL, Lopman BA, Payne DC, et al. Birth Cohort Studies Assessing Norovirus Infection and Immunity in Young Children: A Review. Clin Infect Dis. 2019 Jul 2;69(2):357–365.
   PubMed Web of Science ®Google Scholar
• van Loben Sels JM, Green KY. The Antigenic Topology of Norovirus as Defined by B and T Cell Epitope Mapping: implications for Universal Vaccines and Therapeutics. Viruses. 2019 May 10;11(5):432.
   PubMed Web of Science ®Google Scholar
• Hosmillo M, Chaudhry Y, Nayak K, et al. Norovirus replication in human intestinal epithelial cells is restricted by the interferon-induced JAK/STAT signalling pathway and RNA Polymerase II mediated transcriptional responses. mBio. 2020 Mar 17;11(2):e00215–20. DOI:10.1128/mBio.00215-20
   Google Scholar
• Newman KL, Leon JS. Norovirus immunology: of mice and mechanisms. Eur J Immunol. 2015 Oct;45(10):2742–2757.
   PubMed Web of Science ®Google Scholar
• Lindesmith L, Moe C, Lependu J, et al. Cellular and humoral immunity following Snow Mountain virus challenge. J Virol. 2005 Mar;79(5):2900–2909.
   PubMed Web of Science ®Google Scholar
• Ko G, Jiang ZD, Okhuysen PC, et al. Fecal cytokines and markers of intestinal inflammation in international travelers with diarrhea due to Noroviruses. J Med Virol. 2006 Jun;78(6):825–828.
   PubMed Web of Science ®Google Scholar
• Lindesmith LC, McDaniel JR, Changela A, et al. Sera Antibody Repertoire Analyses Reveal Mechanisms of Broad and Pandemic Strain Neutralizing Responses after Human Norovirus Vaccination. Immunity. 2019 Jun 18;50(6):1530–1541.e8.
   PubMed Web of Science ®Google Scholar
• Atmar RL, Ettayebi K, Ayyar BV, et al. Comparison of Microneutralization and Histo-Blood Group Antigen-Blocking Assays for Functional Norovirus Antibody Detection. J Infect Dis. 2020 Feb 18;221(5):739–743.
   PubMed Web of Science ®Google Scholar
• Debbink K, Donaldson EF, Lindesmith LC, et al. Genetic mapping of a highly variable norovirus GII.4 blockade epitope: potential role in escape from human herd immunity. J Virol. 2012 Jan;86(2):1214–1226.
   PubMed Web of Science ®Google Scholar
• Lindesmith LC, Beltramello M, Donaldson EF, et al. Immunogenetic mechanisms driving norovirus GII.4 antigenic variation. PLoS Pathog. 2012;8(5):e1002705.
   PubMed Web of Science ®Google Scholar
• Debbink K, Lindesmith LC, Donaldson EF, et al. Emergence of new pandemic GII.4 Sydney norovirus strain correlates with escape from herd immunity. J Infect Dis. 2013 Dec 1;208(11):1877–1887.
   PubMed Web of Science ®Google Scholar
• Tohma K, Lepore CJ, Gao Y, et al. Population Genomics of GII.4 Noroviruses Reveal Complex Diversification and New Antigenic Sites Involved in the Emergence of Pandemic Strains. mBio. 2019;10(5):e02202–19.
   PubMed Web of Science ®Google Scholar
• Ramani S, Estes MK, Atmar RL. Correlates of Protection against Norovirus Infection and Disease-Where Are We Now, Where Do We Go? PLoS Pathog. 2016 Apr;12(4):e1005334.
   PubMed Web of Science ®Google Scholar
• Reeck A, Kavanagh O, Estes MK, et al. Serological correlate of protection against norovirus-induced gastroenteritis. J Infect Dis. 2010 Oct 15;202(8):1212–1218.
   PubMed Web of Science ®Google Scholar
• Atmar RL, Bernstein DI, Lyon GM, et al. Serological Correlates of Protection against a GII.4 Norovirus. CVI. 2015 Aug;22(8):923–929.
   Google Scholar
• Knoll BM, Lindesmith LC, Yount BL, et al. Resolution of diarrhea in an immunocompromised patient with chronic norovirus gastroenteritis correlates with constitution of specific antibody blockade titer. Infection. 2016 Aug;44(4):551–554.
   PubMed Web of Science ®Google Scholar
• Bhar S, Jones MK. In Vitro Replication of Human Norovirus. Viruses. 2019 Jun 12;11(6):547.
   PubMed Web of Science ®Google Scholar
• Duizer E, Schwab KJ, Neill FH, et al. Laboratory efforts to cultivate noroviruses. J Gen Virol. 2004 Jan;85(Pt 1):79–87.
   PubMed Web of Science ®Google Scholar
• Jones MK, Watanabe M, Zhu S, et al. Enteric bacteria promote human and mouse norovirus infection of B cells. Science (New York, NY). 2014 Nov 7;346(6210):755–759.
   Google Scholar
• Jones MK, Grau KR, Costantini V, et al. Human norovirus culture in B cells. Nat Protoc. 2015 Dec;10(12):1939–1947.
   PubMed Web of Science ®Google Scholar
• Oka T, Stoltzfus GT, Zhu C, et al. Attempts to grow human noroviruses, a sapovirus, and a bovine norovirus in vitro. PloS One. 2018;13(2):e0178157.
   PubMed Web of Science ®Google Scholar
• Ettayebi K, Crawford SE, Murakami K, et al. Replication of human noroviruses in stem cell-derived human enteroids. Science (New York, NY). 2016 Sep 23;353(6306):1387–1393.
   Google Scholar
• Estes MK, Ettayebi K, Tenge VR, et al. Human Norovirus Cultivation in Nontransformed Stem Cell-Derived Human Intestinal Enteroid Cultures: success and Challenges. Viruses. 2019 Jul 11;11(7):638.
   PubMed Web of Science ®Google Scholar
• Costantini V, Morantz EK, Browne H, et al. Human Norovirus Replication in Human Intestinal Enteroids as Model to Evaluate Virus Inactivation. Emerg Infect Dis. 2018 Aug;24(8):1453–1464.
   PubMed Web of Science ®Google Scholar
• Atmar RL, Bernstein DI, Harro CD, et al. Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med. 2011 Dec 8;365(23):2178–2187.
   PubMed Web of Science ®Google Scholar
• Green KY, Lew JF, Jiang X, et al. Comparison of the reactivities of baculovirus-expressed recombinant Norwalk virus capsid antigen with those of the native Norwalk virus antigen in serologic assays and some epidemiologic observations. J Clin Microbiol. 1993 Aug;31(8):2185–2191.
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Atmar RL, Frey SE, et al. A novel intramuscular bivalent norovirus virus-like particle vaccine candidate–reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults. J Infect Dis. 2014 Dec 1;210(11):1763–1771.
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Atmar RL, Lyon GM, et al. Norovirus Vaccine Against Experimental Human GII.4 Virus Illness: A Challenge Study in Healthy Adults. J Infect Dis. 2015 Mar 15;211(6):870–878.
   PubMed Web of Science ®Google Scholar
• Sherwood J, Mendelman PM, Lloyd E, et al. Efficacy of an intramuscular bivalent norovirus GI.1/GII.4 virus-like particle vaccine candidate in healthy US adults. 7th International Calicivirus Conference; 10/14/2019; Sydney, Australia; 2019.
   Google Scholar
• Kim L, Liebowitz D, Lin K, et al. Safety and immunogenicity of an oral tablet norovirus vaccine, a phase I randomized, placebo-controlled trial. JCI Insight. 2018 Jul 12;3:13.
   Web of Science ®Google Scholar
• Vaxart. Technology: advantages South San Francisco, CA: vaxart. 2018. [cited 2020 Feb 13]. Available from: https://vaxart.com/vaccine-advantages/
   Google Scholar
• Kim L, Martinez CJ, Hodgson KA, et al. Systemic and mucosal immune responses following oral adenoviral delivery of influenza vaccine to the human intestine by radio controlled capsule. Sci Rep. 2016 Nov;24(6):37295.
   Google Scholar
• Liebowitz D, Lindbloom JD, Brandl JR, et al. High titre neutralising antibodies to influenza after oral tablet immunisation: a phase 1, randomised, placebo-controlled trial. Lancet Infect Dis. 2015 Sep;15(9):1041–1048.
   PubMed Web of Science ®Google Scholar
• Liebowitz D, Gottlieb K, Kolhatkar NS, et al. Efficacy, immunogenicity, and safety of an oral influenza vaccine: a placebo-controlled and active-controlled phase 2 human challenge study. Lancet Infect Dis. 2020 Apr;20(4):435–444.
   PubMed Web of Science ®Google Scholar
• Tucker SN, Kolhatkar N, Lin K, et al. Oral Vaccine to Prevent Norovirus Infection Induces Mucosal Homing Plasmablasts and T Follicular Cells in Humans. 7th International Calicivirus Conference; 10/ 14/2019; Sydney, Austrlia; 2019.
   Google Scholar
• Vaxart. Vaxart’s Tableted Oral Bivalent Norovirus Vaccine Meets Primary and Secondary Endpoints in Phase 1b Study. 2019. [cited 2020 Feb 13]. Available from: https://investors.vaxart.com/news-releases/news-release-details/vaxarts-tableted-oral-bivalent-norovirus-vaccine-meets-primary
   Google Scholar
• China approves norovirus vaccine for clinical trial Xinhua News Agency; 2019. [cited 2020 Feb 13]. Available from: http://www.xinhuanet.com/english/2019-06/04/c_138116366.htm
   Google Scholar
• Mattison CP, Cardemil CV, Hall AJ. Progress on norovirus vaccine research: public health considerations and future directions. Expert Rev Vaccines. 2018 Sep;17(9):773–784.
   PubMed Web of Science ®Google Scholar
• Heinimaki S, Hankaniemi MM, Sioofy-Khojine AB, et al. Combination of three virus-derived nanoparticles as a vaccine against enteric pathogens; enterovirus, norovirus and rotavirus. Vaccine. 2019;37(51):7509–7518.
   Web of Science ®Google Scholar
• Blazevic V, Malm M, Arinobu D, et al. Rotavirus capsid VP6 protein acts as an adjuvant in vivo for norovirus virus-like particles in a combination vaccine. Hum Vaccin Immunother. 2016 Mar 3;12(3):740–748.
   PubMed Web of Science ®Google Scholar
• Malm M, Heinimaki S, Vesikari T, et al. Rotavirus capsid VP6 tubular and spherical nanostructures act as local adjuvants when co-delivered with norovirus VLPs. Clin Exp Immunol. 2017 Sep;189(3):331–341.
   PubMed Web of Science ®Google Scholar
• Malm M, Diessner A, Tamminen K, et al. Rotavirus VP6 as an Adjuvant for Bivalent Norovirus Vaccine Produced in Nicotiana benthamiana. Pharmaceutics. 2019 May 11;11(5):229.
   PubMed Web of Science ®Google Scholar
• Craig K, Dai X, Li A, et al. A Lactic Acid Bacteria (LAB)-Based Vaccine Candidate for Human Norovirus. Viruses. 2019 Mar 2;11(3):213.
   PubMed Web of Science ®Google Scholar
• Shioda K, Kambhampati A, Hall AJ, et al. Global age distribution of pediatric norovirus cases. Vaccine. 2015 Aug 7;33(33):4065–4068.
   PubMed Web of Science ®Google Scholar
• Bartsch SM, Lopman BA, Hall AJ, et al. The potential economic value of a human norovirus vaccine for the United States. Vaccine. 2012 Nov 19;30(49):7097–7104.
   PubMed Web of Science ®Google Scholar